Results: There were six post-menopausal women with MOGCT treated at the QCGC compared with 166 pre-menopausal women. In the post-menopausal group of women, there was no mortality directly attributed to germ cell ovarian disease compared with 10 (6.0%) women in the pre-menopausal group.
INTRODUCTION
Malignant ovarian germ cell tumours (MOGCT) are rare with an incidence of 0.5/100 000. 1 They are usually diagnosed in young woman between the age of 10 and 30 years and account for 70% of ovarian cancers in this age group. 2 Germ cell tumours very rarely occur in post-menopausal women. [1] [2] [3] The aim of this study was to evaluate the demographics, treatment and survival of post-menopausal women with MOGCT treated at the Queensland Centre for Gynaecological Cancer (QCGC) over a 35-year period. By comparing this population with all other women with MOGCT, and using the world literature, we hope to optimise management protocols for this subset of MOGCT patients.
MATERIALS AND METHODS
Following Ethics Committee approval (HREC/17/QRBW/522), a retrospective cohort study was undertaken of data retrieved from the QCGC database of all patients diagnosed with MOGCT treated between January, 1981 and February 2017. The demographics, presentation, pathology, treatment and survival outcomes of post-menopausal patients who had a diagnosis of MOGCT was retrieved. All patients in the study had their histopathology confirmed by a gynaecological pathologist and had their management reviewed at a multi-disciplinary Tumour Board Meeting. As per convention, patients with malignant struma ovarii, or other malignant mature cell lines such as carcinoid, were excluded from analysis as these tumours are considered to be a malignant component of a mature teratoma, rather than a primary
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Malignant ovarian germ cell tumours germ cell malignancy per se. Abstracted data was then compared with data from pre-menopausal patients who were diagnosed with MOGCT over the same time period. Case reports of post-menopausal women with MOGCT from the literature were also compared. Given the small number of patients included in this study, demographic data was analysed through descriptive statistics only.
RESULTS
There were six post-menopausal women with MOGCT treated at the Queensland Centre for Gynaecological Cancer over a 35-year period. This still constitutes the largest study in the world literature. The median age at diagnosis was 59 years. The median length of follow-up was 1850 days. The most common histopathological diagnosis was dysgerminoma (4/6), see Table 1 . The stage distribution of post-menopausal women with MOGCT is listed in Table 2 .
All women had initial or completion hysterectomy and bilateral salpingo-oophorectomy. Four of six patients had omentectomy, two patients had a lymphadenectomy and two of six had an appendicectomy. The data set was too small to assess whether the extent of surgery affected outcome. Five women received adjuvant chemotherapy, the majority of which had combinations of Bleomycin, Etoposide and Cisplatin (BEP).
Two patients had disease recurrence. These occurred at one and three years after initial treatment. One patient had stage 1C disease, and the other had stage 2B disease at initial presentation.
Both had initial surgery including bilateral salpingo-oophorectomy and adjuvant chemotherapy. Pathological diagnosis was dygerminoma and malignant teratoma. One case subsequently died from pancreatic cancer four months after diagnosis of recurrence, the other was followed up for four years post-recurrence and is still alive. There was no mortality directly attributed to germ cell ovarian disease. Of the two patients who died, one was from unrelated, metastatic pancreatic cancer, the second was an unknown other cause. Pathology included three yolk sac tumours, two malignant teratomas, two dysgerminomas and one case of embryonal carcinoma.
Fourteen deaths occurred in the pre-menopausal cohort, ten of these deaths were directly due to advanced ovarian cancer. Five of the ten patients who died secondary to malignant ovarian disease were cases with recurrence. Of the five patients who died secondary to ovarian cancer with no recurrence, one patient had stage 3B disease, and three patients were diagnosed with stage 3C disease. The remaining patient was not assigned a stage but was instead described as having poorly differentiated choriocarcinoma. Four patients died from other causes including invasive ductal carcinoma of the breast, a neurosurgical complication, a motor vehicle accident and lastly an unknown other cause. The average age of those who died was 22.
DISCUSSION
The low incidence of MOGCTs in post-menopausal women explains the limited literature available. The majority of published articles are case studies. Parker et al. 3 in their case study of a post-menopausal presentation of yolk sac germ cell tumour reflect on the small number of case reports available.
The difficulty of diagnosis and reduced awareness is thought Generally, MOGCTs are thought to be highly curable with excellent survival outcomes. 4 Increased age over 40 years is widely quoted to be a poor prognostic factor for MOGCTs. Solheim et al. 1 analysed the prognostic significance of age in 2541 patients with MOGCT, concluding that age >40 is associated with a higher mortality risk. Specifically, the risk of death was increased by ninefold in women over 40 with a dysgerminoma and increased by sixfold in women over 40 with a non-dysgerminoma. Solheim's findings reflect the conclusions of Smith et al. 5 and Bower et al. 6 The difference in outcome was postulated to be a result of comorbidities in women with increased age and differing treatment strategies.
By contrast, Murugaesu et al. 7 did not find age to be such a poor prognostic factor.
Interestingly, in this comparison between pre-menopausal and post-menopausal patient populations, there was no directly associated mortality in the post-menopausal cohort. Ten women in the pre-menopausal group died secondary to advanced malignant ovarian germ cell disease. The large difference in sample size between the two cohorts makes it difficult to truly compare mortality rates. Nevertheless, this study questions whether increased age does worsen survival outcome.
In the pre-menopausal and post-menopausal groups of women in this study, there was a similar stage distribution, with the majority of patients diagnosed with stage 1A disease. Moreover, the common pathological diagnosis in both cohorts was dysgerminoma. All patients from both age groups were treated in a tertiary cancer care centre. The need to consider fertility sparing in surgical management of disease in pre-menopausal patients could be a factor in the different mortality rates. However, survival outcomes have been shown to be equivalent in studies comparing conservative surgery with bilateral salpingo-oophorectomy and hysterectomy. 4 The rate of recurrence in the post-menopausal age group was 33.3% compared to 4.7% in the pre-menopausal age group.
There is limited data with respect to recurrence rates in MOGCT.
Nevertheless, the rate of recurrence for women in both age groups in this study was higher than recurrence rates quoted in some series. Brown et al. 4 in their consensus guideline for diagnosis and management of MOGCT suggest that the rate of recurrence is low. For stage 1A disease in patients with initial surgery and adjuvant chemotherapy, Park et al. 8 quote recurrence rates of 2%.
While this review has analysed one of the largest data collections of MOGCT available, this study is still limited by the small cohort of patients assessed. As Brown et al. 4 and Solheim et al. 1 note, in such a rare condition, data is limited globally by a lack of centralised pathology review and data collection. Certainly, more work is required to consolidate data on all cases of MOGCT in post-menopausal age groups worldwide to allow a greater understanding of this disease.
Our review is useful in bringing awareness to the possibility of MOGCTs in post-menopausal women. It also aids in counselling of affected patients as it calls into question previous published predictions of prognosis and outcome in this age group. Mortality rates in women over 50 years of age may not be as high as suggested by published case studies and retrospective reviews.
CONCLUSION
In conclusion, we note that MOGCT is a very rare condition in post-menopausal women, and despite some suggestion in the world literature that survival outcomes may be worse in this patient population, this was not found in our study. Furthermore, we could find no evidence to alter the management of these patients compared with pre-menopausal women.
